146 Results for "

CD34+/CD38- subpopulation

" in MedChemExpress (MCE) Product Catalog:
Products (146)

146 Results for "CD34+/CD38- subpopulation" in MCE Product Catalog:

13
13 Cited Publications
Cat. No.: HY-123999
CAS No.: 1700637-55-3
Purity:  99.26%
Target:  

CD38

Research Areas:  

Metabolic Disease

CD38 inhibitor 1 (compound 78c) is a potent CD38 inhibitor with IC50s of 7.3 nM and 1.9 nM for hCD38 and mouse CD38 .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-P9915
CAS No.: 945721-28-8
Synonyms: Anti-Human CD38, Human Antibody; HuMax-CD38; JNJ-54767414

Target:  

CD38 ADC Antibodies

Research Areas:  

Inflammation/Immunology Cancer

Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-P9915A
CAS No.: 945721-28-8
Synonyms: Anti-Human CD38, Human Antibody (PBS)

Target:  

ADC Antibodies CD38

Research Areas:  

Cancer

Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-N0640
CAS No.: 7084-24-4
Synonyms: Chrysontemin; Cyanidin 3-O-glucoside chloride
Kuromanin chloride (Chrysontemin) is derived from mulberry leaves and has the effect of increasing blood sugar concentration and maintaining lipid metabolism balance to reduce obesity. Kuromanin chloride can inhibit CD38 enzymatic activities .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-129522
CAS No.: 1374663-29-2
Purity:  99.18%
Synonyms: CZ-48
Research Areas:  

Neurological Disease

Sulfo-ara-F-NMN (CZ-48) is a mimetic of nicotinamide mononucleotide (NMN). Sulfo-ara-F-NMN acts selectively, activating SARM1 but inhibiting CD38 (IC50 around 10 μM). Sulfo-ara-F-NMN induces intracellular cyclic ADP-ribose (cADPR) production .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P99048
CAS No.: 2072873-06-2
Synonyms: IBI308

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-19867A
CAS No.: 1191450-19-7
Synonyms: TG-0054 hydrobromide
Target:  

CXCR

Research Areas:  

Cardiovascular Disease Cancer

Burixafor (TG-0054) hydrobromide is a potent CXCR4 antagonist with a pIC50 of 7.4. Burixafor hydrobromide inhibits the binding of CXCL12 to CXCR4, antagonizes CXCL12-induced recruitment of Gαᵢ and β-arrestin2, and blocks the downstream Gαᵢ-mediated inhibitory effect on cAMP signal transduction. Burixafor hydrobromide mobilizes CD34 + hematopoietic stem/progenitor cells (HSPC) from the bone marrow to the peripheral blood. Burixafor hydrobromide can be used for research on autologous hematopoietic stem cell transplantation (ASCT) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P9976
CAS No.: 1461640-62-9
Synonyms: ch38SB19; hu38SB19; SAR-650984

Target:  

CD38 Apoptosis

Research Areas:  

Cancer

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-150508
CAS No.: 2641484-61-7
Purity:  98.60%
MK-0159 is an orally active, potent and selective CD38 inhibitor, with IC50 values of 22, 3, and 70 nM for human, mouse and rat CD38, respectively. MK-0159 also shows good microsomal stability for human and rodent liver microsomes. MK-0159 increases NAD + (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P9976A
CAS No.: 1461640-62-9

Target:  

CD38 Apoptosis

Research Areas:  

Cancer

Isatuximab (anti-CD38) is a monoclonal antibody that targets the transmembrane receptor and extracellular enzyme CD38, a protein highly expressed in hematological malignancies, including multiple myeloma. Isatuximab (anti-CD38) exhibits anti-tumor activity through multiple biological mechanisms, including antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cell phagocytosis, and non-crosslinking direct induction of apoptosis. Isatuximab (anti-CD38) also directly inhibits the extracellular enzyme activity of CD38, which is related to many cellular functions .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-144987
CAS No.: 2597933-17-8
Purity:  98.84%
Target:  

CD38 LAG-3 Tim3 PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

RBN013209 is an orally active small molecule inhibitor of CD38 with an IC50 of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD + to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99730
CAS No.: 2227490-52-8
Synonyms: TAK-079

Target:  

CD38 Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P81098
Synonyms: CD34 antigen; CD34 molecule; Cluster designation 34; Hematopoietic progenitor cell antigen CD34; HPCA1; CD34_HUMAN.

Host:  

Rabbit

Application:  

WB, IHC-P, IHC-F, ICC/IF

Reactivity:  

Human, Mouse

loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-129997
CAS No.: 1154-78-5
Purity:  99.73%
Luteolinidin chloride is a deoxyanthocyanidin isolated from the plant Sorghum bicolor with antioxidant activity. Luteolinidin chloride is a potent CD38 inhibitor (Ki=11.4 μM) and protects the heart from ischemia/reperfusion injury by preserving endothelial nitric oxide synthase (eNOS) function and preventing endothelial dysfunction. Luteolinidin chloride is also a competitive inhibitor of tyrosinase (IC50=3.7 μM) and blocks the production of melanin .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-110208
CAS No.: 32703-82-5
Purity:  98.82%
Research Areas:  

Cancer

BRD9876 is the “rigor” inhibitor that locks kinesin-5 (Eg5) in a state with enhanced microtubules (MTs) binding, leading to bundling and stabilization of MTs. BRD9876 interacts with the tyrosine 104 residue that is part of the α4-α6 allosteric binding pocket. BRD9876 specifically targets microtubule-bound Eg5 and selectively inhibits myeloma over CD34 cells. BRD9876 has the potential for multiple myeloma (MM) research .
loading...
    loading...
Cat. No.: HY-P99616
CAS No.: 2197112-39-1
Synonyms: MOR-202

Target:  

CD38

Research Areas:  

Cancer

Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research .
loading...
    loading...
Cat. No.: HY-P990273

Target:  

CD38 ERK CD1 Apoptosis

Research Areas:  

Cancer

Anti-Mouse CD38 Antibody (NIMR5) is an anti-mouse CD38 IgG2a monoclonal antibody. Anti-Mouse CD38 Antibody (NIMR5) can activate the ERK signaling pathway and promote cell apoptosis. Anti-Mouse CD38 Antibody (NIMR5) can restore T cell function. Anti-Mouse CD38 Antibody (NIMR5) upregulates the expression of CD1d protein and enhances spleen cell proliferation, dendritic cell (DC) and natural killer T cell (NKT) expansion. Anti-Mouse CD38 Antibody (NIMR5) can be used for researches on cancer and immunology such as melanoma and colon cancer .
loading...
    loading...
Cat. No.: HY-P99744
CAS No.: 2254522-19-3
Synonyms: TAK-573

Target:  

CD38

Research Areas:  

Inflammation/Immunology Cancer

Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .
loading...
    loading...
Cat. No.: HY-P990351

Research Areas:  

Inflammation/Immunology

The Anti-CD34 Antibody is a human-derived antibody expressed in CHO, targeting CD34. The Anti-CD34 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD34 Antibody can be referenced from Human IgG1 kappa, Isotype Control (HY-P99001).
loading...
    loading...
Cat. No.: HY-144988
CAS No.: 2597933-78-1
Purity:  98.81%
Target:  

CD38

Research Areas:  

Cancer

CD38 inhibitor 2 is a potent CD38 inhibitor (IC50 = 0.01 ~ 0.1 μΜ).
loading...
    loading...